T1	intervention 99 108	tamoxifen
T2	intervention 113 124	fenretinide
T3	control 565 572	placebo
T4	duration 577 584	2 years
T5	outcome-Measure 598 600	MD
T6	outcome-Measure 605 807	circulating concentrations of follicle-stimulating hormone, luteinizing hormone (LH), estradiol, progesterone, testosterone, androstenedione, dehydro-epiandrosteronesulfate, prolactin, SHBG, and retinol
T7	outcome 1005 1019	increased SHBG
T8	outcome 1033 1104	increases in testosterone, estradiol, and prolactin and reduction in LH
T9	outcome 1140 1204	increased testosterone and androstenedione and decreased retinol
T10	outcome 1206 1208	MD
T11	outcome 1309 1361	10-year cumulative incidence of breast cancer events
